Melola Discovery

← Melola Discovery

Jurnal Tanpa peringkat SINTA

EXPRESSION OF ESTROGEN RECEPTOR (ER), PROGESTERONE RECEPTOR (PR), AND HUMAN EPI- DERMAL GROWTH FACTOR RECEPTOR-2 (HER-2) IN GROWTH AND METASTASES OF BREAST CANCER

Nusantara Medical Science Journal · Vol. ume No. 3 (2017) · hlm. 98–103

DOI
10.20956/nmsj.v1i3.2227
ISSN
2597-7288, 2460-9757
Terbit
2017-08-06
Penerbit
Faculty of Medicine, Hasanuddin University.
Bahasa
en

Abstrak

ABSTRACTIntroduction: Breast cancer is a multifactorial disease as a result of interaction between ge- netic and environmental factors such as hormonal, infection, chemical material, and radiation. Until now, it took as the most occurred of cancer in women, which have the highest mortality in the world. However, its cause still unknown. According to epidemiologic and clinical - laboratory studies, it was found that there are many risk factors which have important roles in female breast cancer like menarche, menopause, endogenous and exogenous hormones, family his- tory (genetics), parity, lactation, obesity, physical activity, diet, alcohol, smoking, environmental factors and history of biopsy and breast examination. The aims of this study to evaluate and compare the clinicopathological features in the four breast cancer subtypes defined by immu- nohistochemistry expression of ER, PR, and HER-2: ER/PR+, HER-2+ (Luminal B); ER/ PR+,HER-2- (Luminal A); ER/PR-, HER-2+ (HER-2 type) and ER-/PR-, HER-2- (Triple nega- tive) type. Methods: This study was a retrospective study of 89 invasive breast cancer. Clini- cal and pathologic features of the four subtypes were compared. Results: ER/PR+, HER2+; ER/PR+, HER2-; ER/PR-, HER2+; and ER/PR-,HER2- types were 10 (11.2%), 35 (39.3%), 27 (30.3%), and 17 (19.1%) samples. Subjects with ER/PR-, HER2- where are likely to be younger (p<0.001). In tumor subtypes with HER2+, the number of subjects with poorly differentiated was larger than the total number of well and moderate differentiated (p < 0.001). There was no significant difference of metastatic to lymph node status in all subtypes. Conclusion: Subtype luminal A of breast cancer have a high number than other subtypes. There was a correlation between overexpression of HER-2 with poorly differentiated of breast cancer but not with a metastatic capability of tumor cells to lymph nodes. Keywords: Luminal A, Luminal B, Her-2 type, Triple negative, breast cancer

Jaringan kolaborasi para penulis

Belum ada rekan penulis di Melola.

Sumber metadata: OAI-PMH (metadata jurnal) https://journal.unhas.ac.id/index.php/jmednus/oai, pertama di-harvest 5 Nov 2026, terakhir terlihat 15 Nov 2026.
Metadata asli (oai_dc)
<oai_dc:dc xmlns="http://www.openarchives.org/OAI/2.0/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/  http://www.openarchives.org/OAI/2.0/oai_dc.xsd">
	<dc:title xml:lang="en">EXPRESSION OF ESTROGEN RECEPTOR (ER), PROGESTERONE RECEPTOR (PR), AND HUMAN EPI- DERMAL GROWTH FACTOR RECEPTOR-2 (HER-2) IN GROWTH AND METASTASES OF BREAST CANCER</dc:title>
	<dc:creator xml:lang="en">Cangara, Husni</dc:creator>
	<dc:description xml:lang="en">ABSTRACTIntroduction: Breast cancer is a multifactorial disease as a result of interaction between ge- netic and environmental factors such as hormonal, infection, chemical material, and radiation. Until now, it took as the most occurred of cancer in women, which have the highest mortality in the world. However, its cause still unknown. According to epidemiologic and clinical - laboratory studies, it was found that there are many risk factors which have important roles in female breast cancer like menarche, menopause, endogenous and exogenous hormones, family his- tory (genetics), parity, lactation, obesity, physical activity, diet, alcohol, smoking, environmental factors and history of biopsy and breast examination. The aims of this study to evaluate and compare the clinicopathological features in the four breast cancer subtypes defined by immu- nohistochemistry expression of ER, PR, and HER-2: ER/PR+, HER-2+ (Luminal B); ER/ PR+,HER-2- (Luminal A); ER/PR-, HER-2+ (HER-2 type) and ER-/PR-, HER-2- (Triple nega- tive) type. Methods: This study was a retrospective study of 89 invasive breast cancer. Clini- cal and pathologic features of the four subtypes were compared. Results: ER/PR+, HER2+; ER/PR+, HER2-; ER/PR-, HER2+; and ER/PR-,HER2- types were 10 (11.2%), 35 (39.3%), 27 (30.3%), and 17 (19.1%) samples. Subjects with ER/PR-, HER2- where are likely to be younger (p&amp;lt;0.001). In tumor subtypes with HER2+, the number of subjects with poorly differentiated was larger than the total number of well and moderate differentiated (p &amp;lt; 0.001). There was no significant difference of metastatic to lymph node status in all subtypes. Conclusion: Subtype luminal A of breast cancer have a high number than other subtypes. There was a correlation between overexpression of HER-2 with poorly differentiated of breast cancer but not with a metastatic capability of tumor cells to lymph nodes. Keywords : Luminal A, Luminal B, Her-2 type, Triple negative, breast cancer</dc:description>
	<dc:publisher xml:lang="en">Faculty of Medicine, Hasanuddin University.</dc:publisher>
	<dc:date>2017-08-06</dc:date>
	<dc:type>info:eu-repo/semantics/article</dc:type>
	<dc:type>info:eu-repo/semantics/publishedVersion</dc:type>
	<dc:type xml:lang="en">Peer-reviewed Article</dc:type>
	<dc:format>application/pdf</dc:format>
	<dc:identifier>https://journal.unhas.ac.id/index.php/jmednus/article/view/2227</dc:identifier>
	<dc:identifier>10.20956/nmsj.v1i3.2227</dc:identifier>
	<dc:source xml:lang="en">Nusantara Medical Science Journal; Volume 1 No. 3 Juli - September 2016; 98-103</dc:source>
	<dc:source>2597-7288</dc:source>
	<dc:source>2460-9757</dc:source>
	<dc:source>10.20956/nmsj.v1i3</dc:source>
	<dc:language>en</dc:language>
	<dc:relation>https://journal.unhas.ac.id/index.php/jmednus/article/view/2227/1238</dc:relation>
	<dc:rights xml:lang="en">Copyright (c) 2017 Nusantara Medical Science Journal</dc:rights>
</oai_dc:dc>